Ex vivo gene therapy is a promising approach to orthopedic regenerative medicine. These strategies typically focus on the constitutive overexpression of osteogenic factors to induce osteoblastic differentiation and matrix mineralization. However, the unregulated production of osteoinductive molecules has also resulted in abnormal bone formation and tumorigenesis. To address these limitations, this work describes a retroviral system to deliver the Runx2 osteoblastic transcription factor under control of the tetracyclineinducible (tet-off) promoter in primary skeletal myoblasts. Runx2 expression was tightly regulated by anhydrotetracyline (aTc) concentration in cell culture media. Osteoblastic gene expression, alkaline phosphatase activity, and matrix mineralization were also controlled by aTc in a dosedependent manner. Additionally, osteoblastic differentiation was temporally regulated by adding and removing aTc from the culture media. Engineered cells were seeded onto collagen scaffolds and implanted intramuscularly in the hind limbs of syngeneic mice. In vivo mineralization by these constructs was regulated by supplementing the drinking water with aTc, as demonstrated by microcomputed tomography and histological analyses. Collectively, these results present a novel system for regulating osteoblastic differentiation of a clinically relevant autologous cell source. This system is significant to developing controlled and effective orthopedic gene therapy strategies and studying the regulation of osteoblastic differentiation.
Introduction
Cell-based therapies have emerged as a promising approach for orthopedic regeneration. 1 However, autologous osteoblastic cell sources are limited by availability, 1 dedifferentiation following in vitro culture, [2] [3] [4] and an age-related decrease in osteogenic capacity. 5 To address these limitations, genetic engineering has become a central component of many regenerative medicine strategies. Forced expression of differentiation factors is commonly used to enhance cell phenotype or modulate cell function to achieve a therapeutic goal. In particular, cell-based approaches to bone tissue engineering often utilize ex vivo gene therapy techniques to induce osteogenesis in non-osteoblastic cell types, including myoblasts 6,7 fibroblasts 8, 9 and pluripotent progenitor cells. [10] [11] [12] [13] These strategies focus on the constitutive overexpression of osteogenic growth and differentiation factors, such as bone morphogenetic proteins (BMPs) [14] [15] [16] [17] or osteoblastic transcription factors, including Runx2. 7, [18] [19] [20] [21] These approaches have been successful in stimulating osteoblastic differentiation and in vivo bone formation. 22 However, unregulated overexpression of these proteins risks aberrant effects of uncontrolled cell signaling, including tumorigenesis 23, 24 and abnormal bone formation. 25, 26 The use of inducible expression systems is a promising method for controlling the behavior of genetically engineered cells. 27 These systems typically drive transgene expression from inducible promoters regulated by non-mammalian transcription factors. The activity of these transcription factors is controlled by exogenous chemical agents which permit ('on' state) or repress ('off' state) transgene expression. In principle, an ex vivo inducible gene therapy strategy entails implanting engineered cells into a bone defect site and maintaining transgene expression in the 'on' condition. When adequate healing has occurred, cells are moved to the 'off' condition to prevent any adverse effects of prolonged transgene overexpression. Additionally, incorporating regulation into these systems allows analysis of unique patterns of transgene expression, including varying duration and magnitude of expression, cycling expression over time, and coordinating the sequential presence of multiple exogenously expressed genes.
The most widely characterized of these systems is the tetracycline-inducible expression system, first described by Gossen and Bujard. 28 The original system utilizes the tetracycline-controlled transactivator (tTA), a fusion protein of the Escherichia coli tet repressor and the activating domain of virion protein 16 of the herpes simplex virus. In the absence of tetracycline, tTA binds the tet operon (tetO) and activates transcription of a downstream gene of interest. However, in the presence of subtoxic levels of tetracycline, the antibiotic binds to tTA, blocking binding of the tetO and subsequent transactivation in a dose-dependent manner. This 'tet-off' version was later modified to a 'tet-on' system where transactivation increases with tetracycline concentration. 29 Despite the greater clinical relevance of the tet-on derivative, the tet-off system is widely reported as having a greater degree of inducibility, including lower expression levels in the 'off' state and higher expression levels in the 'on' state. 30 In addition, this system is compatible in vitro by adding tetracycline to the cell culture media and in vivo by delivering anhydrotetracyline (aTc) via the drinking water.
Both tetracycline-based systems have been used to express BMP transgenes for bone regeneration. 25, 31, 32 BMP-2, the most widely used BMP for osteoinduction, is a secreted growth factor that acts via autocrine and paracrine mechanisms by binding to the extracellular domain of a transmembrance receptor that activates the intracellular Smad signaling pathway. 33 Activated Smads translocate to the nucleus, upregulating and cooperating with the osteoblast-specific transcription factor Runx2 to induce osteoblastic gene expression. 34 Runx2 is essential for osteoblast differentiation 35 and endochondral ossification. 36 Although genetic engineering with BMPs has successfully stimulated osteogenesis in many models, concerns over dosage, release kinetics and target specificity still remain. 37 Forced expression of Runx2, an intracellular effector, enhances the differentiation of an osteogenic cell source 38, 39 and stimulates transdifferentiation of primary skeletal myoblasts into an osteoblastic phenotype.
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Runx2 overexpression has also been recently advocated as a method for maintaining and enhancing an osteoblastic phenotype for bone regeneration, 7, [18] [19] [20] and may overcome potential limitations of genetic engineering with secreted growth factors. However, the ability to direct osteoblastic differentiation with an inducible Runx2 expression system has not been demonstrated.
To generate a system for efficient and regulated transgene expression, we utilized a retroviral tet-off expression system 41 to modulate Runx2 expression. Primary skeletal myoblasts were used as a clinically relevant autologous cell source that is responsive to Runx2 overexpression. 7, 40 We demonstrate that the osteogenic effect of Runx2 overexpression in primary skeletal myoblasts can be regulated by a tetracycline-responsive expression system both in vitro and in vivo. The conversion of Runx2-engineered skeletal myoblasts into an osteoblastic phenotype is inducible, repressible, recoverable after suppression, and dose dependent with tetracycline concentration. This work is significant in developing controlled, effective gene therapy methods for regenerative medicine and represents a novel strategy for investigating the effects of temporal modulation and magnitude of expression levels on osteoblastic differentiation.
Results
Primary skeletal myoblasts from mature male mice were transduced simultaneously with pTJ66-tTA and pXF40-Runx2 retroviral supernatants (Figure 1a ) in the presence of aTc. Anhydrotetracycline is a tetracycline derivative that has higher affinity for tTA and lower antibiotic activity than tetracycline. 42 Cells were passaged in growth media supplemented with 100 ng/ml aTc, 500 mg/ml zeocin, and 500 mg/ml G418 sulfate to select for cells which had integrated both retroviral vectors. After 2 weeks, selective antibiotics were removed from the media and cells were plated for experiments in growth media with 100 ng/ml aTc. Flow cytometry indicated that this cell population strongly expressed enhanced green fluorescent protein (eGFP) from the pTJ66-tTA vector (Figure 1b) , demonstrating successful retroviral transduction and integration, antibiotic selection, and transgene expression. At 24 h after plating, growth media was replaced with differentiation media with the indicated concentration of aTc. Quantitative RT-PCR (qRT-PCR) and Western blotting at 7 days demonstrated high levels of Runx2 expression in the absence of aTc and a dose-dependent decrease in Runx2 expression with aTc concentration (Figure 1c and d) . Although the profile of Runx2 mRNA expression is accurately represented in Figure 1c , the magnitude of change in Runx2 expression is possibly skewed by the detection of antisense Runx2 mRNA transcribed by the 5 0 LTR promoter of pXF40-Runx2. Therefore, the degree of inducibility with this system is likely much greater than the threefold increase observed by qRT-PCR and is more accurately represented by protein levels displayed in Figure 1d . Importantly, no Runx2 protein was detected at high levels of aTc, suggesting that Runx2 expression can be adequately suppressed in the 'off' condition. These results demonstrate a functioning aTc-inducible Runx2 expression system in primary skeletal myoblasts.
Runx2 is a known regulator of many osteoblastspecific genes 35 and repressor of myogenesis. 40 There- 
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CA Gersbach et al fore, we assessed the effects of inducible Runx2 expression on osteoblastic and myogenic gene expression by qRT-PCR after 7 days in the indicated aTc concentration ( Figure 2) . Expression of the osteoblastic markers osteocalcin, bone sialoprotein, osteopontin and Osterix was dependent on aTc concentration and correlated strongly with Runx2 expression. These markers were repressed to levels equivalent to expression by unmodified myoblasts by 10 ng/ml aTc, demonstrating rigorous control of Runx2 expression and transactivation. Conversely, myogenin and troponin T, markers associated with myoblastic differentiation, were regulated in an opposite fashion by aTc, indicating Runx2-dependent suppression of myogenesis. Interestingly, these results suggest that the phenotype of these cells can be controlled by aTc concentration. In the presence of aTc, the cells maintain their predetermined myogenic differentiation program. However, in the absence of aTc, Runx2 expression results in the upregulation of osteoblastic markers and suppression of myogenesis. The functional effects of inducible gene expression on osteoblastic differentiation were examined by alkaline phosphatase biochemical activity at 14 days and matrix mineralization at 28 days via calcium content analysis and von Kossa staining for phosphate deposits ( Figure  3 ). All of these assays followed a similar aTc-dependent pattern as Runx2 and osteoblastic gene expression, with high levels of mineralization in the absence of aTc (high Runx2 levels) and undetectable amounts of alkaline phosphatase activity, calcium and phosphate in as low as 1 ng/ml aTc (low Runx2 levels). Additionally, cultures with X10 ng/ml aTc consisted of large multinucleated myotubes demonstrating myogenic differentiation, whereas cultures without aTc contained mononucleated cells with cobblestone morphology, typical of the osteoblast phenotype. These results suggest that myoblasts engineered with an inducible Runx2 expression system transdifferentiate into an osteoblastic phenotype in the absence of aTc, similar to myoblasts engineered to constitutively express a Runx2 transgene. 40 One major advantage of inducible expression systems is the ability to exogenously manipulate transgene expression over time. To investigate the effects of temporal modulation of Runx2 expression, cells were cultured in differentiation media with or without 100 ng/ml aTc. After 8 days, aTc was either removed or added to the media for another 8 days. Samples were taken every 2 days to measure Runx2 protein levels Runx2-stimulated osteogenesis CA Gersbach et al ( Figure 4a ) and osteocalcin gene expression (Figure 4b ). Both Runx2 and osteocalcin levels increased over 8 days in the absence of aTc, but rapidly returned to background levels after aTc was added back to cultures. There was a short lag time (B2 days) between reaching maximum levels of Runx2 protein and osteocalcin mRNA. Notably, myoblasts that were cultured in differentiation media with 100 ng/ml aTc for 8 days and allowed to undergo myogenic differentiation also upregulated Runx2 and osteocalcin upon induction with similar kinetics as cells that upregulated Runx2 directly after removal of growth media. This finding suggests that both undifferentiated myoblasts and cells in the later stages of terminal myogenic differentiation convert to an osteoblastic phenotype in response to forced Runx2 expression with a similar manner and magnitude. These results indicate that the cellular response to Runx2 activity is not affected by the differentiation state of primary skeletal myoblasts. This hypothesis was corroborated by assessing mineralization in cells cultured with or without 100 ng/ml aTc for 28 and 56 days (Figure 4c ). Cells without aTc incorporated significant amounts of calcium into their matrix, whereas cultures in the presence of aTc did not exhibit detectable levels of calcium incorporation. However, when aTc was added to cultures at 28 days, the rate of calcium incorporation was significantly decreased relative to cells without aTc. The increase in calcium levels despite aTc supplementation may be the result of nucleation of mineral deposits already present and/or continued mineralization during the degradation of Runx2-dependent osteoblastic protein and mRNA molecules. Additionally, myoblasts cultured in differentiation media with aTc for 28 days incorporated higher (Po1E-5) levels of calcium upon removal of aTc than mineralizing cultures at 28 days which upregulated Runx2 before undergoing long-term myogenic differentiation. This result can be explained by the greater cell number at 28 days of culture relative to cultures that upregulated Runx2 beginning 1 day after seeding.
Collectively, these results demonstrate a functioning inducible Runx2 expression system which regulates the conversion of primary skeletal myoblasts into an osteoblastic phenotype. Cells were seeded onto fibrous collagen scaffolds to evaluate this inducible Runx2 expression system in the context of a three-dimensional (3-D) tissue-engineered environment. DNA content gradually decreased over 56 days of in vitro culture (Figure 5a ), potentially due to loss of nonadherent cells and cell death in the construct interior due to nutrient transport limitations associated with static culture. 7, 43 This effect is enhanced in constructs without aTc at 56 days, likely due to the mineral deposits that occur predominantly at the construct periphery. Micro-computed tomography (micro-CT) was used to detect mineralized regions at 28 and 56 days (Figure 5b) . Consistent with the mineralization analyses of monolayer cultures, constructs cultured in 100 ng/ml aTc did not develop any mineralized regions. In contrast, constructs cultured without aTc developed punctate mineralized regions by 56 days. Fourier transform infrared (FT-IR) spectroscopy was used to determine the chemical composition of this mineral phase (Figure 5c ). Spectra of constructs cultured without aTc exhibited peaks representative of a carbonate-containing, biological hydroxyapatite similar to that of cranial bone. 44 Spectra of samples cultured with aTc contained only amide peaks, which are representative of an unmineralized extracellular matrix. Figure 4 Temporal regulation of Runx2-stimulated osteoblastic differentiation. Cells were cultured with or without 100 ng/ml aTc for 8 days before aTc was removed or added back to the media. Cultures were harvested every 2 days to assess (a) Runx2 protein by Western blot or (b) osteocalcin mRNA by quantitative RT-PCR (mean7s.e.m., n ¼ 3, ANOVA Po9E-12). Both Runx2 and osteocalcin increased over 8 days without aTc and were subsequently suppressed to background levels after aTc was added back to the culture media. Additionally, myoblasts cultured in differentiation media with aTc for 8 days upregulated Runx2 and osteocalcin to similar levels as cultures in which aTc was removed at the same time as growth media. (c) Mineralization by cells cultured without aTc for 28 days was significantly decreased by adding aTc back to media as measured by calcium content at 56 days (mean7s.e.m., n ¼ 3, ANOVA Po7E-12). Anhydrotetracyline (100 ng/ml) repressed mineralization in cells for 56 days, but calcium content was enhanced in the same cultures when aTc was removed at 28 days.
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The ultimate application of a tetracycline-inducible Runx2 expression system is to control bone formation in vivo. Therefore, we implanted constructs consisting of collagen scaffolds and Runx2-engineered myoblasts in the hind limb muscles of immunocompetent syngeneic mice for 28 days. Constructs were cultured for 28 days in vitro with or without 100 ng/ml aTc prior to implantation to allow for maturation of the cell-scaffold composite. 19 Drinking water was supplemented with 5% sucrose and 1 mg/ml aTc where indicated. Explants were analyzed by micro-CT and histochemical staining for mineralization and cellular morphology and distribution. Micro-CT showed distinct mineralization of constructs explanted from mice fed with sucrose only (Figure 6a ). These mineralized regions attenuated X-rays similarly to native trabecular bone in the femur and tibia. Explants from mice which were fed aTc displayed no mineralization above background, similar to control constructs seeded with untransduced myoblasts. von Kossa staining for phosphate deposits showed mineralized regions dispersed throughout the implant without aTc, whereas no positive staining was present in constructs with aTc (Figure 6b) . These results show that in vivo mineralization by these engineered cells can be exogenously regulated through aTc supplementation of the drinking water. Hematoxylin and eosin staining showed significantly higher cellularity in constructs without aTc (Figure 6c ), despite equivalent cell numbers at implantation (Figure 5a ). Also, a considerable amount of collagen scaffold (pink regions) was still present in samples with aTc after 28 days of implantation. This finding suggests both a higher degree of scaffold/matrix remodeling as well as cell proliferation and/or recruitment in constructs containing Runx2-expressing cells. Masson's trichrome staining of collagen (blue) displayed large amounts of acellular residual scaffold in implants with aTc ( Figure 6d ). However, in addition to acellular scaffold material, implants without aTc contained significant collagen staining aligned and interwoven in highly cellularized regions, indicating matrix remodeling and/or deposition in a manner resembling early intramembranous bone formation. Histological staining of implants seeded with unmodified skeletal myoblasts and engineered cells in the presence of aTc were similar for all analyses, suggesting no adverse responses to retrovirally transduced cells.
Discussion
The exogenous regulation of Runx2-stimulated osteogenesis is significant for developing safe and controlled methods for gene therapy-based approaches to orthopedic regenerative medicine. This system also represents a useful tool for studying the regulation of osteoblastic differentiation, including the modulation of kinetics and magnitude of gene expression and cellular activity. We have demonstrated dose-dependent control of osteoblastic gene expression and mineralization with aTc concentration as well as suppression of myogenic gene expression in primary skeletal myoblasts. Following induction, osteoblastic markers were suppressible to background levels by addition of aTc to the media, demonstrating effective repression of Runx2-mediated effects in the 'off' condition. The rate of mineralization could also be reduced by adding aTc to the media after 4 weeks of induction, demonstrating the potential to avoid bone overproduction in which bone production extends beyond the defect site. 25, 26 Furthermore, cells precultured in differentiation conditions responded to the removal of aTc in the same fashion as cells in growth media, indicating comparable effects of Runx2 overexpression on myoblasts at distinct stages of differentiation. Finally, mineralization by engineered myoblasts could be regulated with aTc on collagen scaffolds in vitro and in an ectopic implant site in vivo. Greater cell numbers were consistently present on implants without aTc, despite Runx2-stimulated osteogenesis CA Gersbach et al equal cell numbers at implantation. This result is potentially due to differences in proliferation of implanted cells, infiltration of native cells, and/or cell survival. These differences are expected due to the varied autocrine and paracrine signaling of myoblastic (with aTc) and osteoblastic (without aTc) cell types, as well as differences in the structure of the local microenvironment of these samples, including extracellular matrix and mineralization. Collectively, these results show efficient and precise control of Runx2 expression and its downstream effects. Inducible expression systems are notoriously troublesome in establishing successful routines for controlling transgene expression. 27 Typical complications associated with these systems include low levels of induction in the 'on' state, high levels of expression in the 'off' state, insufficient sensitivity to inducer levels, promoter interference of vectors expressing multiple transgenes, gene silencing, and inadequate methods for transferring multiple components of the system into target cells.
The results presented here demonstrate a system with undetectable transgene levels in the off state, high levels of expression in the on state for prolonged culture periods, and tight dose-dependent control of transgene levels over two orders of magnitude of inducer concentration. The success of this system may be attributed to Runx2-stimulated osteogenesis CA Gersbach et al the organization of the retroviral vectors, the antibiotic selection strategy for engineered cells, the cell type used, and/or the potency of Runx2 transcriptional activity. Although tetracycline and its derivatives are known to affect cell activity, the amounts of aTc used in this study are orders of magnitude below toxic concentrations. 42 Furthermore, primary skeletal myoblasts retrovirally engineered to constitutively express a Runx2 transgene 40 showed equivalent levels of osteoblastic differentiation and in vitro and in vivo mineralization with or without aTc (unpublished results). These results indicate that the effect of aTc on overall cell activity is specific to the regulation of Runx2 expression from the retroviral vector. Interestingly, low levels of aTc (1 ng/ml) were necessary to suppress bone sialoprotein and Osterix expression, alkaline phosphatase activity, and mineralization. However, 10 ng/ml aTc was necessary for complete suppression of osteocalcin expression, a direct target gene of Runx2. This suggests that different threshold levels of Runx2 expression may be necessary to activate the many levels of the osteoblastic differentiation cascade. In fact, Runx2 has been proposed as a scaffold for assembling transcriptional machinery in addition to its own transactivation capabilities. 45 Furthermore, forced expression of Runx2 is commonly used to study mechanistic aspects of osteoblastic differentiation. However, currently used techniques do not mimic the physiological expression patterns of this tightly regulated transcription factor with respect to magnitude or duration. Therefore, this inducible expression system represents a promising tool for elucidating the effects of physiological and abnormal expression levels on the multifunctional roles of Runx2 in osteoblast differentiation.
Significant levels of in vivo mineralization and collagen remodeling were detected by ectopically implanted cells in the absence of aTc. These results establish inducible Runx2 expression in primary skeletal myoblasts as a promising strategy for cell-based orthopedic regeneration. However, we did not observe the development of osteocytes, cartilage, or marrow cavities as has been demonstrated by ectopically implanted Runx2-engineered cell lines in immunodeficient mice. 46 This discrepancy may be due to the primary cells and immunocompetent mice used in the present study, and longer implantation times may be necessary for the development of more complex tissues.
We utilized the 'tet-off' system to regulate Runx2-stimulated osteogenesis because it is the most characterized and successful of the available inducible expression systems. However, the clinical application of the 'tet-off' system would require patients to receive tetracycline for an indefinite period of time following bone healing to suppress transgene expression and bone overproduction. Therefore the 'tet-on' system may be more clinically relevant for this application, considering the patient would only receive tetracycline during bone healing. In fact, recent modifications of the 'tet-on' system have shown improved induction levels and lower basal activity in the 'off' state. 47, 48 This system utilized two retroviral vectors to deliver the necessary components of an aTc-inducible Runx2 expression system. 41 The tetracycline-inducible expression system has also been incorporated into a single autoregulatory retroviral cassette, 49 which may circumvent clinical limitations associated with transducing cells with two independent retroviral supernatants. Selfinactivating deletions within retroviral long terminal repeats (LTRs) can also be used to enhance expression from inducible promoters, 32 which may be limited in certain applications due to promoter interference. 50 Furthermore, tetracycline-regulated expression from adeno-associated virus (AAV) vectors 31 may avoid safety concerns associated with insertional mutagenesis and retroviral integrations. 51 In fact, allografts coated with AAV particles encoding osteogenic factors have recently been shown to increase bone healing. 52 Despite the numerous advances in gene transfer and inducible expression systems, 27 it is clear that considerable research is necessary to optimize the effectiveness and clinical utility of these approaches. Additionally, the optimal gene or combinations of genes to deliver is still unclear and may be application specific. In addition to BMPs and the Runx2 transcription factor, promising results have been achieved with strategies focusing on VEGF and RANK-L, 53 Efficacy of these approaches may also be dependent on cell type 38 and in vitro preculture of cell-scaffold composites. 19 Nevertheless, inducible expression systems show significant promise in developing safe and controlled gene therapy strategies for bone tissue engineering.
This work establishes a controlled and effective alternative to genetic engineering with secreted growth factors for gene therapy-based orthopedic regeneration. Additionally, this system represents a method for regulating the magnitude and temporal expression of the osteoblastic phenotype. Finally, this approach will be useful for elucidating biochemical properties of Runx2 activity and the stability of transgene-induced cellular phenotypes.
Materials and methods

Cell culture
Primary skeletal myoblasts were isolated from the tibialis anterior muscles of adult male Balb/c mice and cultured in selective growth media (Ham's F10, 20% fetal bovine serum, 5 ng/ml bFGF (Promega, Madison, WI, USA), 100 U/ml penicillin G sodium, 100 mg/ml streptomycin sulfate), yielding cultures that were greater than 99% myogenic by desmin staining. 59 Cells were cultured on tissue culture plastic dishes coated with 0.01% type I collagen (Vitrogen, Palo Alto, CA, USA) in a humidified 5% CO 2 atmosphere at 371C. Cell culture media and antibiotics were obtained from Invitrogen (Carlsbad, CA, USA), fetal bovine serum was purchased from Hyclone (Logan, UT, USA), and all other cell culture supplements and reagents were acquired from Sigma (St Louis, MO, USA).
Retroviral vectors
Retroviral plasmids pTJ66, pKA23 and pXF40 were generously provided by TJ Murphy. 41 The tTA gene was digested from the pKA23 plasmid with Sfi1
Runx2-stimulated osteogenesis CA Gersbach et al restriction enzyme and ligated into the Sfi1 cloning site of the constitutive retroviral expression vector pTJ66 (Figure 1a) . The pTJ66-tTA retroviral vector uses the promoter activity of the 5 0 LTR to express a single bicistronic mRNA encoding tTA, followed by an internal ribosomal entry site and a zeocin resistance-enhanced green fluorescent protein fusion protein (Zeo(r):eGFP), allowing for noninvasive analysis of transduction efficiency and antibiotic selection for transduced cells (Figure 1b) .
Two Sfi1 restriction sites were inserted into the multiple cloning site of pXF40, the retroviral tetracycline-inducible expression vector. The oligonucleotides 5 0 -CGCGTTGATCAGGCCTTGTAGGCCTAGGGATCCG TAGGCCTACAAGGCCTTCGAAATGCA-3 0 and 5 0 -TTT CGAAGGCCAAGTAGGCCTACGGATCCCTAGGCCTA CAAGGCCTGATCAA-3 0 (Sfi1 sequences underlined) were annealed together, creating Nsi1-and Mlu1-compatible overhangs at each end. This product was then ligated into a linearized pXF40 vector which had been digested with both Nsi1 and Mlu1. Finally, the Runx2 gene was digested from the TJ66 vector with Sfi1 enzyme, and ligated into a Sfi1-digested pXF40 vector. The pXF40-Runx2 vector transcribes the Runx2 gene from the tetracycline-inducible promoter, which consists of seven adjacent copies of the tetO. This vector also constitutively expresses the neomycin resistance gene (Neo(r)) by the 5 0 LTR promoter, allowing for selective purification of transduced cells. All vectors were verified by sequencing the ligation points.
Retroviral transduction
Retroviral stocks were produced by transient transfection of helper virus-free FNX amphotropic producer cells with plasmid DNA as previously described. 38 For production of pXF40-Runx2 retrovirus, cells were maintained in 1 mg/ml aTc, as inactivating conditions enhance retroviral titer of tetracycline-inducible vectors.
Primary myoblasts were cultured up to 12 passages and plated on 0.01% collagen-coated tissue culture polystyrene at 2 Â 10 4 cells/cm 2 24 h prior to retroviral transduction. 60 Cells were transduced with 0.2 ml/cm 2 of equal parts pTJ66-tTA and pXF40-Runx2 retroviral supernatant supplemented with 4 mg/ml hexadimethrine bromide (Polybrene), 5 ng/ml bFGF, and 10% fetal bovine serum, and centrifuged at 2500 r.p.m. (1200 g) for 30 min in a Beckman model GS-6R centrifuge with a swinging bucket rotor. Retroviral supernatant was replaced with growth media and 1 mg/ml aTc. At 48 h following transduction, growth media was supplemented with 1 mg/ml aTc, 500 mg/ml G418 sulfate and 500 mg/ml zeocin. Following 2 weeks of culture in selective growth media in the 'off' condition, cells were plated at 50 000 cells/cm 2 in 0.01% collagen-coated sixwell plates for end point assays. At 24 h after plating, cells were washed twice with phosphate-buffered saline (PBS) to remove residual aTc, and growth media was replaced with differentiation media (aMEM, 10% fetal bovine serum, 100 U/ml penicillin G sodium, 100 mg/ml streptomycin sulfate, 50 mg/ml L-ascorbic acid, 3 mM sodium b-glycerophosphate, and 10 nM dexamethasone) supplemented with the indicated concentration of aTc. Cell culture media was replaced every 3 days until terminal assay, unless noted otherwise.
Osteogenic differentiation
Quantitative RT-PCR, Western blotting, alkaline phosphatase biochemical activity, and von Kossa staining were performed as described previously. 40 Calcium content was determined by dissolving mineralized regions with 1 N acetic acid overnight. Twenty five microliters of appropriately diluted sample was added to 300 ml of arsenazo III-containing Calcium Reagent (Diagnostic Services Ltd, Oxford, CT, USA). The absorbance of the resulting samples was read at 650 nm and compared to a linear standard curve of CaCl 2 in 1 N acetic acid.
Scaffold seeding and analysis
Fibrous collagen disks (5 mm Â 1.5 mm, Kensey Nash, Exton, PA, USA) were incubated overnight in 10% FBS in PBS. Cells (250 000) in 10 ml of growth media were seeded onto each side of the disk in a non-tissue culture treated 24-well plate, for a total of 500 000 cells/ construct. After 4 h, scaffolds were immersed in 2 ml of growth media. After 24 h, growth media was changed to 2 ml of differentiation media with or without 100 ng/ml aTc. Media was replaced every 3 days until terminal assay. FT-IR spectroscopy and DNA content were assessed as described previously. 7 
Intramuscular implantation
Scaffolds seeded with engineered or unmodified myoblasts were cultured for 28 days in vitro and implanted into the hind limbs of 6-week-old immunocompetent male Balb/c mice (Jackson Labs, Bar Harbor, ME, USA) in accordance with an IACUC-approved protocol. A longitudinal 1 cm incision was made in the skin overlying the gastrocnemius muscle, and the muscle was exposed. Scaffolds were inserted into the muscles of both legs through an atraumatic longitudinal split in the direction of the fibers. The muscle was closed over the implants (without suturing) and the skin closed with wound clips. Drinking water containing 5% sucrose with or without 1 mg/ml aTc was replaced every 3 days. At 28 days after implantation mice were euthanized by CO 2 inhalation and lower legs were harvested, skinned, and fixed in 10% neutral buffered formalin.
Micro-computed tomography
Mineralization of 3-D scaffolds was quantified by highresolution X-ray micro-CT using a Scanco Medical VivaCT 40 imaging system (Bassersdorf, Switzerland). Specimens were scanned at 21 mm voxel resolution and evaluated at a threshold corresponding to a linear attenuation of 1.92 cm À1 filter width of 1.2, and filter support of 2.0. The reconstructed and thresholded 3-D images were evaluated using direct distance transformation methods to calculate mineralized matrix volume within each construct. 61 
Histological analysis
Formalin-fixed samples were paraffin embedded for von Kossa-nuclear fast red or hematoxylin-eosin staining, or decalcified with 5% formic acid prior to embedding for Masson's trichrome staining. Sections (5 mm) were deparaffinized and stained as indicated. 
